Clinical Trial

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2023 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-04.
Status change: Not Yet Recruiting → Recruiting 2023-06-12
Trial Details
NCT Number NCT05901428
Lead Sponsor Fudan University
Conditions Hormone Receptor Positive HER-2 Negative Breast Cancer
Enrollment 1,736 participants
Start Date 2023-06-01
Primary Completion 2026-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2023-06-15